Panbela Therapeutics, Inc.
PBLA
$0.2603
-$0.0607-18.91%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 8.41% | -22.30% | -39.25% | -36.73% | -78.06% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 400.69% | -283.25% | -38.29% | -53.32% | -146.18% |
| Change in Net Operating Assets | 253.98% | 2,416.84% | 50.43% | 574.67% | -47.66% |
| Cash from Operations | 68.25% | 82.91% | 3.68% | 38.44% | -319.15% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.00% | -- | -- | -- | 40,100.00% |
| Cash from Investing | -100.00% | -- | -- | -- | 40,100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 39.39% | -- | -- |
| Issuance of Common Stock | -- | -- | -45.93% | -22.03% | -- |
| Repurchase of Common Stock | -- | -420.00% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 103.26% | 28.88% | 96.90% | -- |
| Cash from Financing | 11,678.95% | -100.00% | -48.32% | -11.22% | -480.00% |
| Foreign Exchange rate Adjustments | 250.00% | 0.00% | -100.00% | 200.00% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 101.32% | -110.30% | -158.63% | 385.76% | -296.35% |